Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions

Cabozantinib, a c-MET and vascular endothelial growth factor receptor 2 inhibitor, demonstrated to prolong progression free survival and improve skeletal disease-related endpoints in castration-resistant prostate cancer and in metastatic renal carcinoma. Our purpose is to investigate the direct effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fioramonti, Marco, Santini, Daniele, Iuliani, Michele, Ribelli, Giulia, Manca, Paolo, Papapietro, Nicola, Spiezia, Filippo, Vincenzi, Bruno, Denaro, Vincenzo, Russo, Antonio, Tonini, Giuseppe, Pantano, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386748/
https://www.ncbi.nlm.nih.gov/pubmed/28223547
http://dx.doi.org/10.18632/oncotarget.15390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386748/
https://www.ncbi.nlm.nih.gov/pubmed/28223547
http://dx.doi.org/10.18632/oncotarget.15390

Ejemplares similares